Thank you — you're on the list.

What you'll hear from us, and when

Two things are pending that change what this tool says. When either lands, you get an email. Between them, silence.

1. The 503B final order. The FDA has proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. Comments closed on 30 July 2026 and the final order is pending with no published date. When it publishes, the sourcing picture changes for every clinic dispensing compounded GLP-1s.
2. The peptide rulemaking. July's advisory committee recommendation was advisory. If and when the FDA completes the rulemaking, the answer to "is BPC-157 legal to compound" changes — and until then it has not.

We check for both every weekday. If nothing has changed, we don't email you. A newsletter that arrives whether or not there is news trains you to ignore it.

The full assessment

The free screen asked five questions. The full version works through all eight exposure areas and tells you what to do about what it finds.

Full question set with follow-ups that skip what doesn't apply to you. A weighted risk tier. For every finding: what was found, why it matters, what to review. A prioritised action list ordered by value per hour. And a dated, printable summary to hand to your attorney or medical director.

Every regulatory claim links to its primary source — the FDA announcement, the Federal Register notice, the attorney general's press release — so your counsel can check our work rather than take our word for it.

Get the full assessment — $129

One-time. No subscription. About fifteen minutes to complete.